-
1 Comment
Intra-Cellular Therapies, Inc is currently in a long term uptrend where the price is trading 25.4% above its 200 day moving average.
From a valuation standpoint, the stock is 91.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 107.5.
Intra-Cellular Therapies, Inc's total revenue rose by 20363.9% to $12M since the same quarter in the previous year.
Its net income has dropped by 49.6% to $-61M since the same quarter in the previous year.
Finally, its free cash flow fell by 91.3% to $-68M since the same quarter in the previous year.
Based on the above factors, Intra-Cellular Therapies, Inc gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | US46116X1019 |
| Market Cap | 13B |
|---|---|
| Beta | 0.46 |
| PE Ratio | 0.0 |
| Target Price | 52.4 |
| Dividend Yield | None |
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 23I.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
